Gilead Sciences (GILD) Cash & Equivalents (QoQ) (2009 - 2026)

Gilead Sciences (GILD) Cash & Equivalents (QoQ) (2009 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 0.85%
Dec 31, 2025 3.19%
Sep 30, 2025 42.50%
Jun 30, 2025 -35.10%
Mar 31, 2025 -20.67%
Dec 31, 2024 98.35%
Sep 30, 2024 81.71%
Jun 30, 2024 -41.25%
Mar 31, 2024 -22.47%
Dec 31, 2023 6.66%
Sep 30, 2023 0.02%
Jun 30, 2023 15.56%
Mar 31, 2023 -8.80%
Dec 31, 2022 15.17%
Sep 30, 2022 -0.84%
Jun 30, 2022 10.31%
Mar 31, 2022 -19.52%
Dec 31, 2021 22.38%
Sep 30, 2021 -10.85%
Jun 30, 2021 20.37%